创新药板块今日止跌回暖，截至收盘，中证港股通医药卫生综合指数上涨2.8%，中证创新药产业指数上涨2.7%，恒生港股通创新药指数上涨2.5%，中证生 物科技主题指数上涨2.1%，沪深300医药卫生指数上涨1.8%。Wind数据显示，截至昨日，创新药ETF易方达（516080）和恒生创新药ETF（159316）分别连 续4个和5个交易日获资金净流入。 该指数聚焦港股医疗卫生行 业龙头,由50只医疗器械 、生物药品、化学药及其它 医药卫生行业的港股通股票 组成。 �H 该指数涨跌 创新药ETF易方达德 跟踪中证创新药产业指数 该指数聚焦A股创新药龙头, 由不超过50只主营业务涉 及创新药研发的公司股票 组成,汇聚A股创新药主力 军。 医药ETF ONLY 跟踪沪深300医药卫生指数 该指数聚焦A股医药卫生行 业龙头,由沪深300指数样 本中属于医药卫生行业的公 司股票组成,全面覆盖化学 制药、医疗服务、医疗器械 等未来健康产业细分环节。 4 H 该指数涨跌 1.8% �H 该指数涨跌 2.7% 生物科技ETF (10) 跟踪中证生物科技主题指数 2.8% 该指数聚焦A股生物科技龙 头,由不超过50只业务涉 及基因诊 ...

申万宏源证券指出，中国创新药板块目前具有"创新升级+盈利拐点+出海BD常态化"三重逻辑，这三重逻辑将持续支撑后续 行情，看好中国创新药板块长期的投资价值。 | | 恒生港股通 | 中证落股通 | 中证创新 | 中证牛物 | 沪深300 | | --- | --- | --- | --- | --- | --- | | | 创新药指数 | 医药卫生综 | 药产业指 | 科技主题 | 铁药卫生 | | | | 合指数 | 151 | 指数 | 指数 | | 本周涨跌幅 | -3.0% | -1. 7% | -1. 8% | -0. 7% | -1.2% | | 指数估值 | 滚动市盈率 63.0倍 | 滚动市盈率 31.1倍 | 滚动市盈率 57.9倍 | 滚动市盈率 63.7倍 | 滚动市盈率 33.6倍 | | 指数估值 分位 | 2023年7月 10日发布 | 48. 5% | 88. 8% | 84. 2% | 63.9% | | 跟踪该 | | 恒生创新药 港股通医药 | 创新药ETF | 生物科技 | 矢药ETF | | 指数的 ETF | ETE | ETF | 易方达 | ETF | (51201 ...

Core Insights - The Hang Seng Hong Kong Stock Connect Innovation Drug Index increased by 7.1% this week, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 6.9% [1] - The CSI Innovation Drug Industry Index and the CSI Biotechnology Theme Index saw increases of 5.3% and 3.6%, respectively, with the CSI 300 Medical and Health Index up by 3.4% [1] - The Hang Seng Innovation Drug ETF (159316) experienced a net inflow of nearly 200 million yuan this week, bringing its total size to over 2 billion yuan, a record high [1] Index Performance - Weekly performance: - Hang Seng Innovation Drug Index: +7.1% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +6.9% - CSI Innovation Drug Industry Index: +5.3% - CSI Biotechnology Theme Index: +3.6% - CSI 300 Medical and Health Index: +3.4% [3] - Year-to-date performance: - Hang Seng Innovation Drug Index: +116.2% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: +102.9% - CSI Innovation Drug Industry Index: +43.5% - CSI Biotechnology Theme Index: +31.2% - CSI 300 Medical and Health Index: +22.9% [7] Valuation Metrics - Current rolling P/E ratios: - Hang Seng Innovation Drug Index: 57.7x - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: 30.7x - CSI Innovation Drug Industry Index: 57.3x - CSI Biotechnology Theme Index: 62.3x - CSI 300 Medical and Health Index: 33.0x [3] - Valuation percentile as of July 2023: - Hang Seng Innovation Drug Index: 48.5% - CSI Hong Kong Stock Connect Medical and Health Comprehensive Index: 88.1% - CSI Innovation Drug Industry Index: 82.1% - CSI Biotechnology Theme Index: 60.2% [3] ETF Overview - The Hang Seng Innovation Drug Index has one ETF tracking it, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index has four ETFs [5] - The CSI Innovation Drug Industry Index is tracked by seven ETFs, and the CSI Biotechnology Theme Index has four ETFs [5]

Group 1 - The core viewpoint of the news highlights the strong performance of the innovative drug sector in the first half of the year, driven by successful collaborations, excellent clinical data, and supportive policies [1] - The China Securities report indicates that the innovative drug sector is expected to see a rapid increase in the commercial value of newly launched products due to national policies encouraging innovation [1] - The proportion of domestic innovative drugs in hospital products is anticipated to rise quickly, positioning this sector as one of the best growth segments [1] Group 2 - The index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [4] - The index has shown a rolling price-to-earnings ratio of 59.2 times and an increase of 91.3% since its inception [5] - The biotechnology ETF tracks the China Biotechnology Theme Index, which includes up to 50 stocks related to gene diagnostics, biopharmaceuticals, and other human biotechnology [6] Group 3 - The healthcare ETF tracks the CSI 300 Healthcare Index, covering leading companies in the healthcare sector, including chemical pharmaceuticals, medical services, and medical devices [8] - The CSI 300 Healthcare Index has a rolling price-to-earnings ratio of 33.9 times and has increased by 65.7% since its inception [9]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 0.2%, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index fell by 0.1%. Conversely, the CSI Innovative Drug Industry Index, CSI Biotechnology Theme Index, and CSI 300 Medical and Health Index all increased by 0.1% [1] - The Hang Seng Innovative Drug ETF (159316) experienced a growth of approximately 1 billion yuan in size over the past month, reaching a new historical high of nearly 2 billion yuan [1] Group 2 - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which focuses on leading innovative drug companies in Hong Kong, comprising no more than 40 stocks involved in innovative drug research, development, and production [2] - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index has been tracking since 2017 and includes 50 stocks from the medical device, biopharmaceutical, chemical drug, and other sectors within the Hong Kong Stock Connect [2] - The CSI Innovative Drug Industry Index focuses on leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [2] - The CSI Biotechnology Theme Index targets leading biotechnology companies in the A-share market, including no more than 50 stocks involved in gene diagnosis, biopharmaceuticals, and other human biotechnology sectors [2] - The CSI 300 Medical and Health Index covers leading companies in the medical and health industry within the CSI 300 Index, encompassing various segments of the future health industry, including chemical pharmaceuticals, medical services, and medical devices [2]

Group 1 - The core indices related to the Hong Kong and A-share pharmaceutical sectors have shown significant increases, with the CSI Hong Kong Stock Connect Healthcare Index rising by 5.1%, the Hang Seng Stock Connect Innovative Drug Index by 4.8%, the CSI Innovative Drug Industry Index by 4.6%, the CSI Biotechnology Theme Index by 4%, and the CSI 300 Healthcare Index by 3.6% [1][5][9][13][15] - The Hang Seng Innovative Drug ETF (159316) has seen continuous capital inflow for four consecutive trading days, with its latest scale exceeding 1.8 billion yuan, marking a historical high [1] Group 2 - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading stocks in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related companies [3] - The CSI Innovative Drug Industry Index targets leading innovative drug companies in the A-share market, consisting of no more than 50 stocks involved in innovative drug research and development [7] - The CSI Biotechnology Theme Index centers on leading biotechnology companies in the A-share market, including no more than 50 stocks related to gene diagnosis, biopharmaceuticals, blood products, and other human biotechnology [11] - The CSI 300 Healthcare Index encompasses leading companies in the A-share healthcare sector, covering chemical pharmaceuticals, medical services, medical devices, and other segments of the future health industry [15]

Group 1 - The Hang Seng Hong Kong Stock Connect Innovative Drug Index increased by 3.6% at midday, while the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index rose by 3.5% [1] - The CSI Innovative Drug Industry Index saw a 2.2% increase, and the CSI Biotech Theme Index rose by 1.7% [1] - The CSI 300 Medical and Health Index increased by 1.9% [3] Group 2 - The Hang Seng Innovative Drug ETF (159316) had a trading volume exceeding 500 million yuan, with a net subscription of 54 million units [1] - The index tracked by the Hang Seng Innovative Drug ETF focuses on leading innovative drug companies in Hong Kong, consisting of no more than 40 stocks involved in innovative drug research and development [2] - The rolling price-to-earnings ratio for the Hang Seng Innovative Drug Index is 56.7 times [2] Group 3 - The CSI Hong Kong Stock Connect Medical and Health Comprehensive Index includes 50 stocks from the medical device, biopharmaceutical, and chemical drug sectors [2] - The rolling price-to-earnings ratio for this index is 29.2 times, with a 46.2% increase since its inception in 2017 [2] Group 4 - The CSI Innovative Drug Industry Index focuses on leading innovative drug companies in A-shares, consisting of no more than 50 stocks involved in innovative drug research and development [2] - The rolling price-to-earnings ratio for this index is 52.8 times, with a 79.8% increase since its launch in 2019 [2] Group 5 - The CSI Biotech Theme Index includes up to 50 stocks involved in gene diagnostics, biopharmaceuticals, and other human biotechnology [2] - The rolling price-to-earnings ratio for this index is 58.3 times, with a 72.4% increase since its inception in 2015 [2] Group 6 - The CSI 300 Medical and Health Index covers leading companies in the medical and health sector, including chemical pharmaceuticals, medical services, and medical devices [3] - The rolling price-to-earnings ratio for this index is 32.6 times, with a 58.0% increase since its inception in 2007 [3]

Group 1 - The Shanghai and Shenzhen 300 Pharmaceutical Health Index decreased by 0.3% at midday, while the CSI Biotech Theme Index fell by 0.4%, the CSI Innovative Drug Industry Index dropped by 0.6%, the CSI Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index declined by 1.3%, and the Hang Seng Hong Kong Stock Connect Innovative Drug Index decreased by 1.6% [1][2][3] - The Hang Seng Innovative Drug ETF (159316) saw a net subscription of 14 million units during the half-day trading session [1][2] Group 2 - The Hang Seng Innovative Drug Index focuses on leading innovative drug companies in Hong Kong, consisting of no more than 40 stocks involved in innovative drug research, development, and production [2] - The CSI Hong Kong Stock Connect Pharmaceutical Health Comprehensive Index targets leading companies in the Hong Kong medical and health sector, comprising 50 stocks from medical devices, biopharmaceuticals, and chemical drugs [2] - The CSI Innovative Drug Industry Index concentrates on leading innovative drug companies in A-shares, made up of no more than 50 stocks primarily engaged in innovative drug research and development [2] - The CSI Biotech Theme Index focuses on leading biotech companies in A-shares, including no more than 50 stocks involved in gene diagnostics, biopharmaceuticals, and blood products [2]

Group 1 - The article discusses various ETFs tracking innovative pharmaceutical indices in Hong Kong and mainland China, highlighting their focus on leading companies in the innovative drug sector [1] - The Hang Seng Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Index, which consists of no more than 40 stocks involved in innovative drug research, development, and production [1] - The Hong Kong Stock Connect Medical ETF tracks the CSI Hong Kong Stock Connect Medical and Health Comprehensive Index, comprising 50 stocks from the medical device, biopharmaceutical, chemical drug, and other healthcare sectors [1] Group 2 - The E Fund Innovative Drug ETF tracks the CSI Innovative Drug Industry Index, focusing on leading companies in the A-share innovative drug sector, consisting of no more than 50 stocks involved in innovative drug research and development [1] - The performance metrics of these indices show varying changes, with the Hang Seng Innovative Drug ETF experiencing a decline of 0.1% and the Hong Kong Stock Connect Medical ETF increasing by 0.7% [1] - The E Fund Innovative Drug ETF has seen an increase of 2.7% since its inception, with a rolling price-to-earnings ratio of 54.9 times and an 83.7% valuation percentile since its launch [1]

Group 1 - The China Consumer Electronics Theme Index rose by 2.6%, the China Internet of Things Theme Index increased by 2.4%, the National Robot Industry Index went up by 2.0%, and the China Smart Electric Vehicle Index saw a rise of 1.1% [1] - The E Fund Robot ETF (159530) experienced a net inflow of 950 million yuan last week and received an additional net subscription of 76 million units today, bringing its latest scale to 5.93 billion yuan, a record high [1]